截至发稿，天康生物市值为95亿元。 每经头条（nbdtoutiao）——实施城乡居民增收计划、降准降息等工具灵活高效运用、增加普通高中学 位……深度解读中央经济工作会议 每经AI快讯，天康生物（SZ 002100，收盘价：6.94元）12月12日晚间发布公告称，公司第八届第三十 次董事会临时会议于2025年12月11日在公司11楼4号会议室召开。会议审议了《关于收购新疆羌都畜牧 科技有限公司51%股权暨签署 <股权收购协议> 的议案》等文件。 2025年1至6月份，天康生物的营业收入构成为：生猪养殖占比32.2%，饲料占比27.51%，农产品加工占 比16.37%，玉米收储行业占比14.75%，兽药占比5.44%。 （记者 王瀚黎） ...

Core Viewpoint - TianKang Biological announced the resignation of its general manager, Cheng Hui, due to approaching retirement age, while appointing Xu Heng as the new general manager [1] Company Summary - Cheng Hui's resignation was accepted by the board, and he will continue to serve as a director and a member of the Strategic and Investment Committee [1] - The company's revenue composition for the first half of 2025 is as follows: pig farming 32.2%, feed 27.51%, agricultural product processing 16.37%, corn storage 14.75%, and veterinary medicine 5.44% [1] - As of the report, TianKang Biological has a market capitalization of 9.8 billion yuan [1]

Group 1 - The company TianKang Biological (SZ 002100) held its 28th temporary board meeting on October 29, 2025, via communication voting to review the "2025 Q3 Report" and other documents [1] - For the first half of 2025, the revenue composition of TianKang Biological was as follows: pig farming accounted for 32.2%, feed accounted for 27.51%, agricultural product processing accounted for 16.37%, corn storage industry accounted for 14.75%, and veterinary medicine accounted for 5.44% [1] - As of the report date, the market capitalization of TianKang Biological was 10.6 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market transformation and a new "slow bull" pattern emerging [1]

Company Overview - TianKang Biological announced the resignation of Deputy General Manager Zheng Dongsheng due to personal work adjustments, effective immediately upon submission to the board [1] - After his resignation, Zheng Dongsheng will no longer hold any positions within the company or its subsidiaries [1] Financial Performance - For the first half of 2025, TianKang Biological's revenue composition is as follows: pig farming accounted for 32.2%, feed accounted for 27.51%, agricultural product processing accounted for 16.37%, corn storage accounted for 14.75%, and veterinary medicine accounted for 5.44% [1] - As of the report date, TianKang Biological has a market capitalization of 9.2 billion yuan [1]